53
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Synthesis, Spectral Characterization and Antitubercular Study of Novel Quinoline Schiff Base and Its Metal Complexes

, &
Pages 523-538 | Received 01 Dec 2020, Accepted 20 Apr 2021, Published online: 13 Jul 2021
 

Abstract

Synthesis of novel Schiff base from 2-hydroxy-6-methylquinolin-3-carbaldehyde and 4-methyl-benzenesulfonohydrazide has been carried out in the present work. Also, the metal complexes of Cu(II), Ni(II), Co(II) and Cd(II) have been synthesized. Schiff base and metal complexes were characterized by various analytical techniques such as CHN analyzer, XRD, FT-IR, UV-Visible, ESR, 1H NMR, 13C NMR, MASS and TGA. Very low value of molar conductance indicates non electrolytic nature of the complexes. The analytical data shows that the ratio of metal to ligand in Cu(II), Ni(II), Co(II) and Cd(II) complexes is 1:2. FT-IR spectral data suggest that the ligand behaves as a tridentate O, N, O donor system. Magnetic susceptibility measurements reveal the paramagnetic behavior of all the complexes except Cd-complex. Further, the Schiff base and the metal complexes were screened for their antimycobacterial activity against M. Bovis BCG and M. tuberculosis H37Ra strains. Compounds 7, 8a, 8c & 8d exhibit very promising results against M. Bovis BCG and MTB H37Ra strains. Among all, Cu-complex shows highest MIC (2.8) value.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.